Endocyte rallies as vintafolide PRECEDENT results published

After tumbling some 20% late last week on news that the vintafolide monotherapy arm in TARGET was (in the opinion of the DSMB) not likely to be declared superior to docetaxel in terms of PFS, Endocyte (ECYT +10.9%) recoups some of its losses as Phase 2 data shows vintafolide plus PLD resulted in a median PFS of 5 months in women with platinum-resistant ovarian cancer versus 2.7 months for the PLD alone group.

The Hazard Ratio was 0.63.

The results were published in the Journal of Clinical Oncology. (PR)

Comments (1)
  • Scientist on Stocks
    , contributor
    Comments (416) | Send Message
    These results are public knowledge since months. Its correlation with today's price action is unconvincing. Probably some institutional buying or buy recommendation or something else.
    15 Oct 2013, 04:33 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs